Protecting AGYW in Gauteng from Lenacapavir misinformation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The trial focuses on adolescent girls and young women in Gauteng, South Africa, exploring if inoculation against misinformation about Lenacapavir can influence their willingness to use the injectable PrEP. It compares groups exposed to misinformation with and without a protective inoculation strategy. The intervention includes a diabetes information component and an enhanced inoculation message, delivered to eligible participants aged 18-29 who are HIV-negative or of unknown status. The study is led by the University of Pennsylvania with local collaborators and sites in Johannesburg. Outcomes center on shifts in intentions to receive Lenacapavir after exposure to misinformation.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Female (cisgender or transgender)
* Age 18-29 years
* Self-reported history of sexual activity in the past 12 months
* Self-reported HIV-negative status or unknown HIV status at enrolment
* Willing and able to provide consent
* Able to read and understand English

Exclusion Criteria:

Unwilling or unable to provide consent for study participation.

Where it's running

• Health Economics and Epidemiology Research Office, University of the Witwatersrand
  Johannesburg, South Africa Recruiting

Study contacts

• Study coordinator: Teniola Egbe, MPH, MBE
• Email: tegbe@pennmedicine.upenn.edu
• Phone: 215-898-2939

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Improving vaccine confidence through a culturally-specific video in Southeast Asia

  This study tests whether a culturally-specific video can help people in Southeast Asia feel more confident about vaccines by addressing common misinformation.

  Recruiting University of California, Berkeley · Berkeley, California · NCT06947187

• Flurpiridaz F-18 PET/CT to Find Parathyroid Adenomas

  This study tests whether Flurpiridaz F-18 PET/CT can better detect abnormal parathyroid glands in adults with primary hyperparathyroidism before surgery.

  Recruiting Early Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07910097

• Low-intensity focused ultrasound targeting the subthalamic nucleus for OCD

  A short test is being done to see if a wearable, non-invasive ultrasound device can safely and tolerably help adults with OCD by targeting a brain region called the subthalamic nucleus.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07887633

• Safe firearm storage: preferred device choice vs. standard cable locks

  This study tests whether giving people a choice of storage devices for firearms leads to safer storage at home compared with just sending cable locks.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT07886983

• Add-on anti-inflammatory therapy for adults with depression and high inflammation

  This study tests whether adalimumab, given with your regular antidepressant Lexapro, can improve depressive symptoms in adults with major depressive disorder and high inflammation.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07845604

• FAP PET/CT in adults with pulmonary TB

  This early-phase study tests whether a FAP PET/CT scan can map lung fibrosis in adults with pulmonary TB before starting treatment and after cure.

  Recruiting Early Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07830771

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.